Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.38 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7661580 | 0.87 | LTA4H (0.39) | CA4PPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL4516165 | 0.79 | CA4 (0.41) | CA4PPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL27482970 | 0.79 | CA4 (0.41) | CA4PPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL9240409 | 0.79 | L3MBTL1 (0.41) | PPARGPPARAMTNR1AMTNR1BLTA4H | |
| SCHEMBL9238203 | 0.75 | MTNR1A (0.37) | PPARGPPARAMTNR1AMTNR1BLTA4H | |
| SCHEMBL43675 | 0.74 | MTNR1A (0.42) | CA4MTNR1AMTNR1BLTA4HGAA | |
| SCHEMBL9353539 | 0.74 | MTNR1A (0.42) | CA4MTNR1AMTNR1BLTA4HGAA | |
| SCHEMBL8893040 | 0.71 | CA4 (0.46) | CA4PPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL446679 | 0.71 | MTNR1A (0.40) | CA4MTNR1AMTNR1BGAACYP1A2 | |
| SCHEMBL3906412 | 0.70 | CA4 (0.50) | CA4PPARGPPARAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989446-B2 | 4-amino 5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-01-13 | — | — | US | disclosed |
| US-7834002-B2 | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1740574-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105778-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | disclosed |
| EP-0787135-A1 | WATER-SOLUBLE EPIPODOPHYLLOTOXIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF AS A DRUG AND FOR TREATING CANCER | PIERRE FABRE MEDICAMENT (FR) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012727-A1 | WATER-SOLUBLE EPIPODOPHYLLOTOXIN DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF AS A DRUG AND FOR TREATING CANCER | PIERRE FABRE MEDICAMENT (FR) | 1996-05-02 | — | — | WO | disclosed |
| US-5114946-A | An enantiomorphs and a vehicle for drug deliversy | AMERICAN CYANAMID COMPANY (US) | 1992-05-19 | — | — | US | disclosed |
| EP-0334593-A1 | Chiral azetidinone epoxides | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0334590-A2 | 3-(Substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | ELI LILLY AND COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0334592-A2 | A process for preparing 3-unsubstituted cephalosporins and 1-carba(dethia)cephalosporins | ELI LILLY AND COMPANY (US) | 1989-09-27 | — | — | EP | disclosed |
| EP-0324562-A1 | 1-Carba(dethia)-3-cephem derivatives | ELI LILLY AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| EP-0321636-A2 | Enhancers for the transdermal flux of certain 1,4-Dihydropyridine derivatives | AMERICAN CYANAMID COMPANY (US) | 1989-06-28 | — | — | EP | disclosed |
| EP-0317780-A1 | Sustained (controlled) release delivery system for substituted dihydropyridine calcium channel blockers | AMERICAN CYANAMID COMPANY (US) | 1989-05-31 | — | — | EP | disclosed |
| EP-0299728-A2 | Carbonylation process for beta-lactam antibiotics | ELI LILLY AND COMPANY (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0294601-A2 | Transdermal delivery of pharmaceuticals | AMERICAN CYANAMID COMPANY (US) | 1988-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | CA4 2299/4885PPARG 442/4885PPARA 994/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | CA4 2299/4885PPARG 442/4885PPARA 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.